AstraZeneca Turns Gaze On Global Impact Of Diabetes Crisis
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - If viral diseases were the scourge of the nineteenth and twentieth centuries, diseases born of more effective healthcare and wealth might represent the next threat. Prominent among them is diabetes, which causes about 5 percent of deaths around the world every year
You may also be interested in...
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators
AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan
TOKYO - AstraZeneca K.K., a fully owned Japanese subsidiary of AstraZeneca, has announced plans to market type 2 diabetes treatment dapagliflozin jointly with Bristol-Meyers Squibb in Japan, a company spokesman said
Avandia Market Share Stabilizing, GSK CEO Garnier Says
In his last earnings presentation, Garnier says it is unclear whether the type 2 diabetes drug will become a growth driver again.